Thu, Aug 21, 2014, 10:24 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

  • jetmanbash jetmanbash Dec 26, 2013 9:58 PM Flag

    Liver problems bring on CKD:

    Kidney biomarkers and differential diagnosis of patients with cirrhosis and acute kidney injury
    Hepatology, 12/24/2013

    Belcher JM, et al. – Acute kidney injury (AKI) is common in patients with cirrhosis and associated with significant mortality. The most common etiologies of AKI in this setting are pre–renal azotemia (PRA), acute tubular necrosis (ATN) and hepatorenal syndrome (HRS). Accurately distinguishing the etiology of AKI is critical as treatments differ markedly. Urinary biomarkers of kidney injury are elevated in patients with cirrhosis and AKI due to ATN. Incorporating biomarkers into clinical decision making has the potential to more accurately guide treatment by establishing which patients have structural injury underlying their AKI.

 
AEGR
30.11-0.98(-3.15%)Aug 21 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.